Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBN6W2)

Drug Name
US10035778, Example 12 Drug Info
Synonyms
SCHEMBL19067109; BDBM279571; US10035778, Example 12; Preparation of (3S)-3-[3-chloro-5-methyl-phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid
Cross-matching ID
PubChem CID
130177126
TTD Drug ID
DMBN6W2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Integrin beta-8 (ITGB8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MEDI8367 DM7L053 Chronic kidney disease GB61 Phase 1 [2]
US10035778, Example 16 DMJ53DR N. A. N. A. Patented [1]
US10035778, Example 1 DM28XHN N. A. N. A. Patented [1]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin beta-8 (ITGB8) TTIF29E ITB8_HUMAN Inhibitor [1]

References

1 Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778.
2 ClinicalTrials.gov (NCT04365218) A Phase I Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of MEDI8367 Administered as Single Ascending Doses in Healthy Subjects, and as a Single Dose in Healthy Subjects of Japanese-descent and in Subjects With Chronic Kidney Disease. U.S.National Institutes of Health.